Zoetis (ZTS) Projected to Post Earnings on Thursday

Zoetis (NYSE:ZTS) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of $1.37 per share and revenue of $2.31 billion for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Zoetis Price Performance

NYSE ZTS opened at $171.71 on Tuesday. The stock’s fifty day moving average price is $169.26 and its 200 day moving average price is $179.21. Zoetis has a 1 year low of $144.80 and a 1 year high of $200.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The company has a market cap of $77.47 billion, a price-to-earnings ratio of 32.28, a PEG ratio of 2.77 and a beta of 0.90.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent research reports. Piper Sandler reduced their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday. Stifel Nicolaus reduced their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Finally, Morgan Stanley lowered their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus target price of $214.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.